A Mathematical Model for Predicting Patient Responses to Combined Radiotherapy with CTLA-4 Immune Checkpoint Inhibitors

The purpose of this study was to develop a cell–cell interaction model that could predict a tumor’s response to radiotherapy (RT) combined with CTLA-4 immune checkpoint inhibition (ICI) in patients with hepatocellular carcinoma (HCC). The previously developed model was extended by adding a new term representing tremelimumab, an inhibitor of CTLA-4. The distribution of the new immune activation term was derived from the results of a clinical trial for tremelimumab monotherapy (NCT01008358). The proposed model successfully reproduced longitudinal tumor diameter changes in HCC patients treated with tremelimumab (complete response = 0%, partial response = 17.6%, stable disease = 58.8%, and progressive disease = 23.6%). For the non-irradiated tumor control group, adding ICI to RT increased the clinical benefit rate from 8% to 32%. The simulation predicts that it is beneficial to start CTLA-4 blockade before RT in terms of treatment sequences. We developed a mathematical model that can predict the response of patients to the combined CTLA-4 blockade with radiation therapy. We anticipate that the developed model will be helpful for designing clinical trials with the ultimate aim of maximizing the efficacy of ICI-RT combination therapy.

[1]  S. Pitroda,et al.  Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization , 2022, Neoplasia.

[2]  Wen Hu,et al.  Preclinical Study of Plasmodium Immunotherapy Combined with Radiotherapy for Solid Tumors , 2022, Cells.

[3]  J. Kulbacka,et al.  Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment , 2022, Cells.

[4]  H. Paganetti,et al.  Mathematical modeling to simulate the effect of adding radiotherapy to immunotherapy and application to hepatocellular carcinoma. , 2021, International Journal of Radiation Oncology, Biology, Physics.

[5]  I. Kelson,et al.  The Potentiation of Anti-Tumor Immunity by Tumor Abolition with Alpha Particles, Protons, or Carbon Ion Radiation and Its Enforcement by Combination with Immunoadjuvants or Inhibitors of Immune Suppressor Cells and Checkpoint Molecules , 2021, Cells.

[6]  E. Deutsch,et al.  Radiotherapy–immunotherapy combinations – perspectives and challenges , 2020, Molecular oncology.

[7]  J. Koivunen,et al.  Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection , 2020, International journal of molecular sciences.

[8]  H. Paganetti,et al.  A Tumor-Immune Interaction Model for Hepatocellular Carcinoma based on measured Lymphocyte Counts in Patients undergoing Radiotherapy. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  J. Seong,et al.  Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma , 2019, Strahlentherapie und Onkologie.

[10]  F. Hodi,et al.  The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. , 2019, International journal of radiation oncology, biology, physics.

[11]  Timothy A. Chan,et al.  The hallmarks of successful anticancer immunotherapy , 2018, Science Translational Medicine.

[12]  F. Barlesi,et al.  Immunologically effective dose: a practical model for immuno-radiotherapy , 2018, Oncotarget.

[13]  J. Welsh,et al.  Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy. , 2018, Immunotherapy.

[14]  Eduardo G Moros,et al.  Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy , 2018, Scientific Reports.

[15]  Harald Paganetti,et al.  Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model , 2017, Scientific Reports.

[16]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[17]  C. N. Coleman,et al.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.

[18]  S. Demaria,et al.  Current clinical trials testing the combination of immunotherapy with radiotherapy , 2016, Journal of Immunotherapy for Cancer.

[19]  B. Fox,et al.  Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy , 2016, PloS one.

[20]  Yoichi Watanabe,et al.  A mathematical model of tumor growth and its response to single irradiation , 2016, Theoretical Biology and Medical Modelling.

[21]  C. June,et al.  Radiation and immunotherapy: a synergistic combination. , 2013, The Journal of clinical investigation.

[22]  J. Prieto,et al.  A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. , 2013, Journal of hepatology.

[23]  H. Rhim,et al.  Growth rate of new hepatocellular carcinoma after percutaneous radiofrequency ablation: evaluation with multiphase CT. , 2008, AJR. American journal of roentgenology.

[24]  B. Erickson,et al.  Estimate of radiobiologic parameters from clinical data for biologically based treatment planning for liver irradiation. , 2008, International journal of radiation oncology, biology, physics.

[25]  Oscar Sotolongo-Costa,et al.  Assessment of cancer immunotherapy outcome in terms of the immune response time features. , 2007, Mathematical medicine and biology : a journal of the IMA.

[26]  J. A. Santos-Miranda,et al.  Immune system-tumour efficiency ratio as a new oncological index for radiotherapy treatment optimization. , 2007, Mathematical medicine and biology : a journal of the IMA.

[27]  D. Bigner,et al.  Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function , 2007, Clinical Cancer Research.

[28]  L. M. Molina,et al.  Behavior of tumors under nonstationary therapy , 2002, math-ph/0203057.

[29]  W. Ross,et al.  Radiation damage and immune suppression in splenic mononuclear cell populations , 1997, Clinical and experimental immunology.

[30]  A. Perelson,et al.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.

[31]  M. Akiyama,et al.  Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. , 1990, Radiation research.

[32]  S. Demaria,et al.  Combination of radiotherapy and immune checkpoint inhibitors. , 2015, Seminars in radiation oncology.

[33]  K. Lumniczky,et al.  The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences. , 2015, Cancer letters.